Growth Hormone and Hormone Replacement Therapy for Anti-Aging
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
For anti-aging use in healthy adults specifically, human evidence shows no demonstrated frailty reversal or longevity benefit and is contradicted by mechanistic and epidemiological data suggesting low GH/IGF-1 signaling is associated with reduced cancer and mortality risk; the Endocrine Society clinical guideline and 2023 scientific statement explicitly advise against this use.
Reference only. Not medical advice.
Growth hormone (GH) is a pituitary hormone that stimulates growth in childhood and continues to regulate metabolism, muscle mass, and bone density in adults, largely through its downstream mediator insulin-like growth factor 1 (IGF-1). GH and IGF-1 levels decline gradually with normal aging, a change sometimes called 'somatopause,' which led some clinicians and anti-aging practitioners to propose that restoring youthful GH levels in healthy older adults could reverse aspects of aging such as loss of muscle mass, increased body fat, and reduced energy. This theory has been tested and has not held up as a net benefit in healthy adults. Growth hormone replacement therapy has clear, well-established, and government-approved medical use in adults with confirmed growth hormone deficiency, typically caused by pituitary tumors, surgery, radiation, or trauma, where it improves body composition, exercise capacity, bone density, and quality of life; the Endocrine Society's clinical practice guideline addresses this population specifically. In contrast, for healthy adults without diagnosed deficiency, no prospective study has shown that giving growth hormone reverses frailty, slows functional aging, or extends lifespan. Meanwhile, evidence of harm is meaningful: growth hormone excess (as seen in the disease acromegaly) is strongly associated with increased cancer risk, cardiovascular disease, diabetes, and reduced lifespan, and even therapeutic-range dosing in older adults without deficiency has been associated with side effects such as joint pain, fluid retention, carpal tunnel syndrome, insulin resistance, and gynecomastia, without a demonstrated compensating longevity benefit. The Endocrine Society and the American Association of Clinical Endocrinology both state explicitly that GH should not be prescribed for anti-aging purposes in adults without confirmed deficiency, and mainstream endocrinology regards 'anti-aging GH' as an off-label, unproven, and potentially harmful use, despite its continued marketing at some private longevity and hormone clinics globally, particularly where regulatory oversight of compounding and hormone prescribing is loosely enforced.
Growth hormone (GH) is a pituitary hormone that stimulates growth in childhood and continues to regulate metabolism, muscle mass, and bone density in adults.
Safety in detail
Growth hormone use in adults without confirmed deficiency is associated with joint pain, fluid retention, insulin resistance, carpal tunnel syndrome, and theoretical increased cancer risk (extrapolated from acromegaly data), and major endocrine societies advise against its use for anti-aging purposes.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Growth hormone was first purified and used therapeutically for pituitary dwarfism in children starting in the 1950s and 1960s using hormone extracted from cadaver pituitary glands, a supply-limited and eventually unsafe method (linked to Creutzfeldt-Jakob disease transmission) that was replaced by genetically engineered recombinant human growth hormone approved by the FDA in 1985. Interest in growth hormone for anti-aging in healthy older adults grew after a widely publicized 1990 New England Journal of Medicine study reported body composition improvements in a small group of older men given GH, a finding that was amplified well beyond what the study supported and helped fuel a private anti-aging GH industry. Subsequent, larger, and longer studies did not confirm meaningful functional or longevity benefit in healthy adults, and by the early 2010s the Endocrine Society had issued clinical guidelines explicitly restricting GH therapy to adults with confirmed growth hormone deficiency, a position reaffirmed in a 2023 scientific statement distinguishing normal aging from endocrine disease.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Growth Hormone and Hormone Replacement Therapy for Anti-Aging. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.